853680-11-2

Upstream product

• 315-30-0 4-hydroxypyrazolo(3,4-d)pyrimidine 
• 5399-92-8 4-chloro-1H-pyrazolo[3,4-d]pyrimidine 
• 90914-41-3 3-bromo-4-chloropyrazolo<3,4-d>pyrimidine 
• 98-09-9 benzenesulfonyl chloride 

Downstream Products

• 853680-12-3 4-(1-benzenesulfonyl-3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester 
• 853680-14-5 (R)-[2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazin-1-yl]-1-(4-chlorobenzyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 1351094-12-6 3-{[3-bromo-1-(phenylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yI]amino}-N-methyl-4-[(1-methylethyl)oxy]benzenesulfonamide 
• 1351087-82-5 N-methyl-4-[(1-methylethyl)oxy]-3-[(3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzenesulfonamide 
• 1351087-81-4 3-{[3-(3,6-dihydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino}-N-methyl-4-[(1-methylethyl)oxy]benzenesulfonamide 
• 1351087-79-0 3-{[3-(3-furanyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino}-N-methyl-4-[(1-methylethyl)oxy]benzenesulfonamide 
• 1351087-78-9 N-methyl-4-[(1-methylethyl)oxy]-3-{[3-(5-methyl-2-furanyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino}benzenesulfonamide 
• 1351087-75-6 3-{[3-(2-furanyl )-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino}-N-methyl-4-[(1-methylethyl)oxy]benzenesulfonamide 
• 1351087-73-4 N-methyl-4-[(1-methylethyl)oxy]-3-{[3-(1H-methyl-1H-pyrazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino}benzenesulfonamide 
• 1351087-71-2 N-methyl-4-[(1-methylethyl)oxy]-3-{[3-(1-methyl-1H-pyrazol-4-yl )-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino}benzenesulfonamide 
• 1351087-57-4 3-[(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-methyl-4-[(1-methylethyl)oxy]benzenesulfonamide 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS

Disclosed are compounds having the Formula (I), wherein X, Y, Z, R1, R2 and R3 are as defined herein, and methods of making and using the same.

AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.